Ikena to examine combination of oncologic with AstraZeneca's Tagrisso for NSCLC
Mohammed Haneefa Nizamudeen         

Ikena Oncology (NASDAQ:IKNA) has inked an agreement with AstraZeneca to examine its Â candidate IK-930 in combination with AstraZeneca's (NASDAQ:AZN) Tagrisso (osimertinib)Â for non-small cell lung cancer.
IK-930, known as a TEAD inhibitor, is currently in a phase 1 trial in patients with advanced solid tumors forÂ malignant mesothelioma. The US FDA granted Fast Track designationfor this indication.
Seeking Alpha's Quant Rating views Ikena (IKNA) as a strong sell.